They are not intended to represent clinical evidence in humans, and Epithalon has not been approved by the FDA, EMA, or any other regulatory authority for any indication
For those sensitive to needles, a numbing cream may be applied to the injection site to reduce any discomfort during the procedure
Theoretically, combining AOD-9604 with beta-3 agonists (mirabegron) could amplify lipolytic effects, though no clinical reports describe this interaction
If pain, range of motion, or function has not moved by week 4, the dose or delivery method needs adjusting rather than extending the same protocol blindly
These findings are preliminary and may not translate to effects in humans
812 Weeks: Enhanced tissue integrity, reduced scarring, and improved endurance